Article
Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis.
Journal of acquired immune deficiency syndromes (1999) - 1 Jan 2012
Rimsky Laurence, Vingerhoets Johan, Van Eygen Veerle, Eron Joseph, Clotet Bonaventura, Hoogstoel Annemie, Boven Katia, Picchio Gaston
Abstract excerpt
Genotypic and phenotypic characterization was performed of HIV-1 isolates from treatment-naive HIV-1-infected patients experiencing virologic failure (VF) during treatment with the nonnucleoside reverse transcriptase inhibitor (NNRTIs) rilpivirine or efavirenz in the pooled phase 3 studies ECHO and THRIVE. Among 686 patients receiving rilpivirine, 72 (10%) experienced VF versus 39 of 682 (6%) receiving efavirenz....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.